ALK and non-small cell lung carcinoma: Treatment duration, as a surrogate intermediate clinical endpoint instead of PFS, may correlate better with OS and may be more accurate to evaluate the efficacy of crizotinib in sequential therapy for ALK‐positive NSCLC patients.